Tumor BRCA mutation or high genomic LOH identify ovarian cancer patients likely to respond to rucaparib: Interim results for ARIEL2 clinical trial

Swisher, E.; Oza, A.M.; Coleman, Robert L.; Scott, Clare L.; Lin, Kevin K.; Dominy, Erin; Maloney, Lara; Goble, Sandra; Yelensky, Roman; McNeish, Iain A.

doi:10.1016/j.ygyno.2015.04.024

Cited by 7 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based upon genomic signature, women were classified as having biomarker negative, BRCA-mutant, or BRCA-like tumors, defined as tumors that were BRCA-wild type but had evidence of genome-wide loss of heterozygosity. The study found that women with BRCA-mutant tumors had a response rate of 69% and median PFS of 9.4 months, while response rates and median PFS were 30% and 7.1 months and 13% and 3.7 months for BRCA-like and biomarker-negative tumors, respectively(20). …”

Section: Poly-adp-ribose Polymerase (Parp) Inhibitionmentioning

confidence: 99%

Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know

Liu

Westin

2016

Gynecologic Oncology

View full text Add to dashboard Cite

Precision medicine is a rapidly evolving area in the treatment of gynecologic malignancies. Advances in sequencing technology have resulted in an increasing wealth of data regarding the genomic characteristics of ovarian, endometrial, and cervical cancers. These vast new datasets of information have led to novel insights into potential vulnerabilities and therapeutic targets for these cancers. However, unraveling the complex molecular changes within cancer cells to determine how best to attack these targets and to identify effective biomarkers of response remains a significant challenge. In this article, we review the current status of biomarker-driven targeted therapy in gynecologic malignancies.

show abstract

Section: Poly-adp-ribose Polymerase (Parp) Inhibitionmentioning

confidence: 99%

Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know

Liu

Westin

2016

Gynecologic Oncology

View full text Add to dashboard Cite

show abstract

“…Currently, such assays interrogate a tumor for either specific mutations in genes known to oversee the process (BRCA1/2, RAD51, PALB2, etc.) or for “evidence” of a poorly functioning HR apparatus, such as global loss of heterozygosity[4, 36]. Such findings, combined with the availability of PARP inhibitors, have ushered in a new paradigm for treating patients across a number of malignancies.…”

mentioning

confidence: 99%